异丙酚
医学
脑电双频指数
麻醉
镇静
咪唑安定
低氧血症
随机对照试验
丸(消化)
临床终点
芬太尼
外科
作者
Yu Lun Lo,Ting Lin,Yueh‐Fu Fang,Tsai Yu Wang,Hao Cheng Chen,Chun Liang Chou,Fu‐Tsai Chung,Chih Hsi Kuo,Po Hao Feng,Chien Ying Liu,Han Pin Kuo
出处
期刊:PLOS ONE
[Public Library of Science]
日期:2011-11-23
卷期号:6 (11): e27769-e27769
被引量:60
标识
DOI:10.1371/journal.pone.0027769
摘要
There are safety issues associated with propofol use for flexible bronchoscopy (FB). The bispectral index (BIS) correlates well with the level of consciousness. The aim of this study was to show that BIS-guided propofol infusion is safe and may provide better sedation, benefiting the patients and bronchoscopists.After administering alfentanil bolus, 500 patients were randomized to either propofol infusion titrated to a BIS level of 65-75 (study group) or incremental midazolam bolus based on clinical judgment to achieve moderate sedation. The primary endpoint was safety, while the secondary endpoints were recovery time, patient tolerance, and cooperation.The proportion of patients with hypoxemia or hypotensive events were not different in the 2 groups (study vs. control groups: 39.9% vs. 35.7%, p = 0.340; 7.4% vs. 4.4%, p = 0.159, respectively). The mean lowest blood pressure was lower in the study group. Logistic regression revealed male gender, higher American Society of Anesthesiologists physical status, and electrocautery were associated with hypoxemia, whereas lower propofol dose for induction was associated with hypotension in the study group. The study group had better global tolerance (p<0.001), less procedural interference by movement or cough (13.6% vs. 36.1%, p<0.001; 30.0% vs. 44.2%, p = 0.001, respectively), and shorter time to orientation and ambulation (11.7±10.2 min vs. 29.7±26.8 min, p<0.001; 30.0±18.2 min vs. 55.7±40.6 min, p<0.001, respectively) compared to the control group.BIS-guided propofol infusion combined with alfentanil for FB sedation provides excellent patient tolerance, with fast recovery and less procedure interference.ClinicalTrials. gov NCT00789815.
科研通智能强力驱动
Strongly Powered by AbleSci AI